NUVB · Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Market Cap
1.345B
52 Wk Range
$3.71 - $9.75
Previous Close
$3.81
Open
$3.76
Volume
2,862,434
Day Range
$3.72 - $3.91
Enterprise Value
981.7M
Cash
663.4M
Avg Qtr Burn
-38.56M
Insider Ownership
17.09%
Institutional Own.
72.21%
Qtr Updated
Sep 30th 2026
